Previous 10 | Next 10 |
Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022. Aurinia (AUPH), which commerci...
Aurinia Pharma press release (NASDAQ:AUPH): Q4 GAAP EPS of -$0.25 beats by $0.02. Revenue of $23.4M (-53.2% Y/Y) beats by $1.57M. For further details see: Aurinia Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $23.4M beats by $1.57M
$23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full year 2021 2021 readout of strong results from AURORA 2 continuation study fuels momentum for year two of launch Cash and cash equivalent...
Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q4 earnings results on Monday, February 28th, before market open. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $21.83M (-56.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 dow...
AUPH, AZRE, BFLY, BRK.B, CVEO, CWEN, DEA, DQ, FREY, GLP, ITRI, JLL, KOS, LINC, MRSN, NLSN, PRTY, RETA, RIDE, TGNA, VRS, VTRS, XPEL, XRAY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials for Q4 2021 at the end of February. Canada-based Aurinia (NASDAQ:AUPH) markets LUPK...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its fourth quarter and year end 2021 financial results on Monday, February 28, 2021, before markets open. Aurinia’s management team will host a conference call/webcast a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation at the 11 th Annual Leerink Global Healthcare Conference (February 14-18, 2022). The presentation will take place virtually on Wednesday...
Biogen (NASDAQ:BIIB) is scheduled to announce Q4 earnings results on Thursday, February 3rd, before market open. The consensus EPS Estimate is $3.38 (-26.2% Y/Y) and the consensus Revenue Estimate is $2.62B (-8.1% Y/Y). Over the last 2 years, BIIB has beaten EPS estimates 88% of the time and ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences. H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday,...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...